APO Research
Talk to an analyst

APO RESEARCH · REPORT

RNA-Targeted Small Molecule Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global RNA-Targeted Small Molecule Drugs Industry Growth and Trends Forecast to 2032

4 January 2026112 pages

Choose your research edition.

Industry ResearchRNA-Targeted Small Molecule Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal RNA-Targeted Small Molecule Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal RNA-Targeted Small Molecule Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal RNA-Targeted Small Molecule Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal RNA-Targeted Small Molecule Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

According to APO Research, the global RNA-Targeted Small Molecule Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for RNA-Targeted Small Molecule Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the RNA-Targeted Small Molecule Drugs market include Roche, Novartis, PTC Therapeutics, Biogen, Accent Therapeutics, Anima Biotech, Arrakis Pharmaceuticals, Epics Therapeutics and Expansion Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global RNA-Targeted Small Molecule Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The RNA-Targeted Small Molecule Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global RNA-Targeted Small Molecule Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to RNA-Targeted Small Molecule Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global RNA-Targeted Small Molecule Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

RNA-Targeted Small Molecule Drugs Market by Company

Roche

Novartis

PTC Therapeutics

Biogen

Accent Therapeutics

Anima Biotech

Arrakis Pharmaceuticals

Epics Therapeutics

Expansion Therapeutics

Gotham Therapeutics

H3 Biomedicine

Ribometrix

Skyhawk Therapeutics

STORM Therapeutics

Twentyeight-Seven Therapeutics

RNA-Targeted Small Molecule Drugs Segment by Type

mRNA Translation Regulation

RNA Splicing Modification

Direct RNA Targeting

Indirect RNA Targeting - Epitranscriptomics

RNA-Targeted Small Molecule Drugs Segment by Application

SMA

Oncology

Lung Fibrosis

Huntington's Disease

Others

RNA-Targeted Small Molecule Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global RNA-Targeted Small Molecule Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of RNA-Targeted Small Molecule Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of RNA-Targeted Small Molecule Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of RNA-Targeted Small Molecule Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026) & (US$ Million) Table 3. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2021-2026) Table 4. Global RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032) & (US$ Million) Table 5. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2027-2032) Table 6. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global RNA-Targeted Small Molecule Drugs Market Size by Type (2021-2026) & (US$ Million) Table 8. Global RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2026) Table 9. Global RNA-Targeted Small Molecule Drugs Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global RNA-Targeted Small Molecule Drugs Market Size Share Forecasted by Type (2027-2032) Table 11. North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global RNA-Targeted Small Molecule Drugs Market Size by Application (2021-2026) & (US$ Million) Table 23. Global RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2026) Table 24. Global RNA-Targeted Small Molecule Drugs Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global RNA-Targeted Small Molecule Drugs Market Size Share Forecasted by Application (2027-2032) Table 26. North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. RNA-Targeted Small Molecule Drugs Industry Trends Table 37. RNA-Targeted Small Molecule Drugs Industry Drivers Table 38. RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges Table 39. RNA-Targeted Small Molecule Drugs Industry Restraints Table 40. Global RNA-Targeted Small Molecule Drugs Revenue by Company (US$ Million) & (2021-2026) Table 41. Global RNA-Targeted Small Molecule Drugs Revenue Market Share by Company (2021-2026) Table 42. Global RNA-Targeted Small Molecule Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global RNA-Targeted Small Molecule Drugs Key Company Headquarters & Area Served Table 44. Global RNA-Targeted Small Molecule Drugs Company, Product Type & Application Table 45. Global RNA-Targeted Small Molecule Drugs Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global RNA-Targeted Small Molecule Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Roche Company Information Table 49. Roche Business Overview Table 50. Roche RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Roche RNA-Targeted Small Molecule Drugs Product Portfolio Table 52. Roche Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis RNA-Targeted Small Molecule Drugs Product Portfolio Table 57. Novartis Recent Development Table 58. PTC Therapeutics Company Information Table 59. PTC Therapeutics Business Overview Table 60. PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 62. PTC Therapeutics Recent Development Table 63. Biogen Company Information Table 64. Biogen Business Overview Table 65. Biogen RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Biogen RNA-Targeted Small Molecule Drugs Product Portfolio Table 67. Biogen Recent Development Table 68. Accent Therapeutics Company Information Table 69. Accent Therapeutics Business Overview Table 70. Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 72. Accent Therapeutics Recent Development Table 73. Anima Biotech Company Information Table 74. Anima Biotech Business Overview Table 75. Anima Biotech RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio Table 77. Anima Biotech Recent Development Table 78. Arrakis Pharmaceuticals Company Information Table 79. Arrakis Pharmaceuticals Business Overview Table 80. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio Table 82. Arrakis Pharmaceuticals Recent Development Table 83. Epics Therapeutics Company Information Table 84. Epics Therapeutics Business Overview Table 85. Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 87. Epics Therapeutics Recent Development Table 88. Expansion Therapeutics Company Information Table 89. Expansion Therapeutics Business Overview Table 90. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 92. Expansion Therapeutics Recent Development Table 93. Gotham Therapeutics Company Information Table 94. Gotham Therapeutics Business Overview Table 95. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 97. Gotham Therapeutics Recent Development Table 98. H3 Biomedicine Company Information Table 99. H3 Biomedicine Business Overview Table 100. H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio Table 102. H3 Biomedicine Recent Development Table 103. Ribometrix Company Information Table 104. Ribometrix Business Overview Table 105. Ribometrix RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio Table 107. Ribometrix Recent Development Table 108. Skyhawk Therapeutics Company Information Table 109. Skyhawk Therapeutics Business Overview Table 110. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 112. Skyhawk Therapeutics Recent Development Table 113. STORM Therapeutics Company Information Table 114. STORM Therapeutics Business Overview Table 115. STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 117. STORM Therapeutics Recent Development Table 118. Twentyeight-Seven Therapeutics Company Information Table 119. Twentyeight-Seven Therapeutics Business Overview Table 120. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio Table 122. Twentyeight-Seven Therapeutics Recent Development Table 123. North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 124. North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) & (US$ Million) Table 125. North America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2026) Table 126. North America RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 127. North America RNA-Targeted Small Molecule Drugs Market Share Forecast by Country (2027-2032) Table 128. Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 129. Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) & (US$ Million) Table 130. Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2026) Table 131. Europe RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 132. Europe RNA-Targeted Small Molecule Drugs Market Share Forecast by Country (2027-2032) Table 133. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 134. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) & (US$ Million) Table 135. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2026) Table 136. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 137. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share Forecast by Country (2027-2032) Table 138. Latin America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) & (US$ Million) Table 140. Latin America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2026) Table 141. Latin America RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. Latin America RNA-Targeted Small Molecule Drugs Market Share Forecast by Country (2027-2032) Table 143. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026) & (US$ Million) Table 145. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2026) Table 146. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share Forecast by Country (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. RNA-Targeted Small Molecule Drugs Product Image Figure 3. Global RNA-Targeted Small Molecule Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global RNA-Targeted Small Molecule Drugs Market Size (2021-2032) & (US$ Million) Figure 5. Global RNA-Targeted Small Molecule Drugs Market Share by Region: 2025 VS 2032 Figure 6. Global RNA-Targeted Small Molecule Drugs Market Share by Region (2021-2032) Figure 7. North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. mRNA Translation Regulation Image Figure 13. Global mRNA Translation Regulation Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. RNA Splicing Modification Image Figure 15. Global RNA Splicing Modification Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Direct RNA Targeting Image Figure 17. Global Direct RNA Targeting Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Indirect RNA Targeting - Epitranscriptomics Image Figure 19. Global Indirect RNA Targeting - Epitranscriptomics Market Size YoY Growth (2021-2032) & (US$ Million) Figure 20. Global RNA-Targeted Small Molecule Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 21. Global RNA-Targeted Small Molecule Drugs Market Share by Type 2025 VS 2032 Figure 22. North America RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032) Figure 23. Europe RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032) Figure 24. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032) Figure 25. Latin America RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032) Figure 26. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Share by Type (2021-2032) Figure 27. SMA Image Figure 28. Global SMA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Oncology Image Figure 30. Global Oncology Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Lung Fibrosis Image Figure 32. Global Lung Fibrosis Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Huntington's Disease Image Figure 34. Global Huntington's Disease Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Others Image Figure 36. Global Others Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Global RNA-Targeted Small Molecule Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global RNA-Targeted Small Molecule Drugs Market Share by Application 2025 VS 2032 Figure 39. North America RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032) Figure 40. Europe RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032) Figure 41. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032) Figure 42. Latin America RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032) Figure 43. Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Share by Application (2021-2032) Figure 44. Global Top 5 and 10 RNA-Targeted Small Molecule Drugs Players Market Share by Revenue in 2025 Figure 45. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 46. North America RNA-Targeted Small Molecule Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. North America RNA-Targeted Small Molecule Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. North America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 49. Europe RNA-Targeted Small Molecule Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe RNA-Targeted Small Molecule Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 52. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Asia-Pacific RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 55. Latin America RNA-Targeted Small Molecule Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America RNA-Targeted Small Molecule Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 58. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 60. Middle East & Africa RNA-Targeted Small Molecule Drugs Market Share by Country (2021-2032) Figure 61. Years Considered Figure 62. Research Process Figure 63. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Translation Regulation
  • RNA Splicing Modification
  • Direct RNA Targeting
  • Indirect RNA Targeting - Epitranscriptomics
Applications
  • SMA
  • Oncology
  • Lung Fibrosis
  • Huntington's Disease
  • Others
Companies covered
  • Roche
  • Novartis
  • PTC Therapeutics
  • Biogen
  • Accent Therapeutics
  • Anima Biotech
  • Arrakis Pharmaceuticals
  • Epics Therapeutics
  • Expansion Therapeutics
  • Gotham Therapeutics
  • H3 Biomedicine
  • Ribometrix
  • Skyhawk Therapeutics
  • STORM Therapeutics
  • Twentyeight-Seven Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global RNA-Targeted Small Molecule Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2032)
  5. 1.4.1 Global RNA-Targeted Small Molecule Drugs Market Size by Region (2021-2026)
  6. 1.4.2 Global RNA-Targeted Small Molecule Drugs Market Size by Region (2027-2032)
  7. 1.5 Key Regions RNA-Targeted Small Molecule Drugs Market Size (2021-2032)
  8. 1.5.1 North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate (2021-2032)
2 RNA-Targeted Small Molecule Drugs Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 mRNA Translation Regulation
  3. 2.1.2 RNA Splicing Modification
  4. 2.1.3 Direct RNA Targeting
  5. 2.1.4 Indirect RNA Targeting - Epitranscriptomics
  6. 2.2 Global RNA-Targeted Small Molecule Drugs Market Size by Type
  7. 2.2.1 Global RNA-Targeted Small Molecule Drugs Market Size Overview by Type (2021-2032)
  8. 2.2.2 Global RNA-Targeted Small Molecule Drugs Historic Market Size Review by Type (2021-2026)
  9. 2.2.3 Global RNA-Targeted Small Molecule Drugs Market Size Forecasted by Type (2027-2032)
  10. 2.3 Global RNA-Targeted Small Molecule Drugs Market Size by Regions
  11. 2.3.1 North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026)
  12. 2.3.2 Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026)
  13. 2.3.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026)
  14. 2.3.4 South America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026)
  15. 2.3.5 Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Type (2021-2026)
3 RNA-Targeted Small Molecule Drugs Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 SMA
  3. 3.1.2 Oncology
  4. 3.1.3 Lung Fibrosis
  5. 3.1.4 Huntington's Disease
  6. 3.1.5 Others
  7. 3.2 Global RNA-Targeted Small Molecule Drugs Market Size by Application
  8. 3.2.1 Global RNA-Targeted Small Molecule Drugs Market Size Overview by Application (2021-2032)
  9. 3.2.2 Global RNA-Targeted Small Molecule Drugs Historic Market Size Review by Application (2021-2026)
  10. 3.2.3 Global RNA-Targeted Small Molecule Drugs Market Size Forecasted by Application (2027-2032)
  11. 3.3 Global RNA-Targeted Small Molecule Drugs Market Size by Regions
  12. 3.3.1 North America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026)
  13. 3.3.2 Europe RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026)
  14. 3.3.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026)
  15. 3.3.4 South America RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026)
  16. 3.3.5 Middle East and Africa RNA-Targeted Small Molecule Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 RNA-Targeted Small Molecule Drugs Industry Trends
  2. 4.2 RNA-Targeted Small Molecule Drugs Industry Drivers
  3. 4.3 RNA-Targeted Small Molecule Drugs Industry Opportunities and Challenges
  4. 4.4 RNA-Targeted Small Molecule Drugs Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by RNA-Targeted Small Molecule Drugs Revenue (2021-2026)
  2. 5.2 Global RNA-Targeted Small Molecule Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global RNA-Targeted Small Molecule Drugs Key Company Headquarters & Area Served
  4. 5.4 Global RNA-Targeted Small Molecule Drugs Company, Product Type & Application
  5. 5.5 Global RNA-Targeted Small Molecule Drugs Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global RNA-Targeted Small Molecule Drugs Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 RNA-Targeted Small Molecule Drugs Players Market Share by Revenue in 2025
  9. 5.6.3 2025 RNA-Targeted Small Molecule Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Roche
  2. 6.1.1 Roche Company Information
  3. 6.1.2 Roche Business Overview
  4. 6.1.3 Roche RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Roche RNA-Targeted Small Molecule Drugs Product Portfolio
  6. 6.1.5 Roche Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis RNA-Targeted Small Molecule Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 PTC Therapeutics
  14. 6.3.1 PTC Therapeutics Company Information
  15. 6.3.2 PTC Therapeutics Business Overview
  16. 6.3.3 PTC Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 PTC Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  18. 6.3.5 PTC Therapeutics Recent Developments
  19. 6.4 Biogen
  20. 6.4.1 Biogen Company Information
  21. 6.4.2 Biogen Business Overview
  22. 6.4.3 Biogen RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Biogen RNA-Targeted Small Molecule Drugs Product Portfolio
  24. 6.4.5 Biogen Recent Developments
  25. 6.5 Accent Therapeutics
  26. 6.5.1 Accent Therapeutics Company Information
  27. 6.5.2 Accent Therapeutics Business Overview
  28. 6.5.3 Accent Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Accent Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  30. 6.5.5 Accent Therapeutics Recent Developments
  31. 6.6 Anima Biotech
  32. 6.6.1 Anima Biotech Company Information
  33. 6.6.2 Anima Biotech Business Overview
  34. 6.6.3 Anima Biotech RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Anima Biotech RNA-Targeted Small Molecule Drugs Product Portfolio
  36. 6.6.5 Anima Biotech Recent Developments
  37. 6.7 Arrakis Pharmaceuticals
  38. 6.7.1 Arrakis Pharmaceuticals Company Information
  39. 6.7.2 Arrakis Pharmaceuticals Business Overview
  40. 6.7.3 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Arrakis Pharmaceuticals RNA-Targeted Small Molecule Drugs Product Portfolio
  42. 6.7.5 Arrakis Pharmaceuticals Recent Developments
  43. 6.8 Epics Therapeutics
  44. 6.8.1 Epics Therapeutics Company Information
  45. 6.8.2 Epics Therapeutics Business Overview
  46. 6.8.3 Epics Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Epics Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  48. 6.8.5 Epics Therapeutics Recent Developments
  49. 6.9 Expansion Therapeutics
  50. 6.9.1 Expansion Therapeutics Company Information
  51. 6.9.2 Expansion Therapeutics Business Overview
  52. 6.9.3 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Expansion Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  54. 6.9.5 Expansion Therapeutics Recent Developments
  55. 6.10 Gotham Therapeutics
  56. 6.10.1 Gotham Therapeutics Company Information
  57. 6.10.2 Gotham Therapeutics Business Overview
  58. 6.10.3 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 Gotham Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  60. 6.10.5 Gotham Therapeutics Recent Developments
  61. 6.11 H3 Biomedicine
  62. 6.11.1 H3 Biomedicine Company Information
  63. 6.11.2 H3 Biomedicine Business Overview
  64. 6.11.3 H3 Biomedicine RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 H3 Biomedicine RNA-Targeted Small Molecule Drugs Product Portfolio
  66. 6.11.5 H3 Biomedicine Recent Developments
  67. 6.12 Ribometrix
  68. 6.12.1 Ribometrix Company Information
  69. 6.12.2 Ribometrix Business Overview
  70. 6.12.3 Ribometrix RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Ribometrix RNA-Targeted Small Molecule Drugs Product Portfolio
  72. 6.12.5 Ribometrix Recent Developments
  73. 6.13 Skyhawk Therapeutics
  74. 6.13.1 Skyhawk Therapeutics Company Information
  75. 6.13.2 Skyhawk Therapeutics Business Overview
  76. 6.13.3 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 Skyhawk Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  78. 6.13.5 Skyhawk Therapeutics Recent Developments
  79. 6.14 STORM Therapeutics
  80. 6.14.1 STORM Therapeutics Company Information
  81. 6.14.2 STORM Therapeutics Business Overview
  82. 6.14.3 STORM Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 STORM Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  84. 6.14.5 STORM Therapeutics Recent Developments
  85. 6.15 Twentyeight-Seven Therapeutics
  86. 6.15.1 Twentyeight-Seven Therapeutics Company Information
  87. 6.15.2 Twentyeight-Seven Therapeutics Business Overview
  88. 6.15.3 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Twentyeight-Seven Therapeutics RNA-Targeted Small Molecule Drugs Product Portfolio
  90. 6.15.5 Twentyeight-Seven Therapeutics Recent Developments
7 North America
  1. 7.1 North America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  3. 7.3 North America RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  3. 8.3 Europe RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  3. 10.3 South America RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa RNA-Targeted Small Molecule Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst